JP2021522296A5 - - Google Patents

Info

Publication number
JP2021522296A5
JP2021522296A5 JP2020561032A JP2020561032A JP2021522296A5 JP 2021522296 A5 JP2021522296 A5 JP 2021522296A5 JP 2020561032 A JP2020561032 A JP 2020561032A JP 2020561032 A JP2020561032 A JP 2020561032A JP 2021522296 A5 JP2021522296 A5 JP 2021522296A5
Authority
JP
Japan
Prior art keywords
compound
salt
cells
vaccination
immunostimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522296A (ja
JP7557374B2 (ja
Filing date
Publication date
Priority claimed from GBGB1807051.6A external-priority patent/GB201807051D0/en
Priority claimed from GBGB1807819.6A external-priority patent/GB201807819D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/061093 external-priority patent/WO2019211294A1/en
Publication of JP2021522296A publication Critical patent/JP2021522296A/ja
Publication of JP2021522296A5 publication Critical patent/JP2021522296A5/ja
Priority to JP2024159173A priority Critical patent/JP2024170634A/ja
Application granted granted Critical
Publication of JP7557374B2 publication Critical patent/JP7557374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561032A 2018-04-30 2019-04-30 免疫増強剤としてのウロリチンa Active JP7557374B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159173A JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンa

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1807051.6 2018-04-30
GBGB1807051.6A GB201807051D0 (en) 2018-04-30 2018-04-30 Biological enhancer
GB1807819.6 2018-05-14
GBGB1807819.6A GB201807819D0 (en) 2018-05-14 2018-05-14 Biological enhancer
PCT/EP2019/061093 WO2019211294A1 (en) 2018-04-30 2019-04-30 Urolithin a as immune enhancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159173A Division JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンa

Publications (3)

Publication Number Publication Date
JP2021522296A JP2021522296A (ja) 2021-08-30
JP2021522296A5 true JP2021522296A5 (cg-RX-API-DMAC10.html) 2022-05-13
JP7557374B2 JP7557374B2 (ja) 2024-09-27

Family

ID=66379918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561032A Active JP7557374B2 (ja) 2018-04-30 2019-04-30 免疫増強剤としてのウロリチンa
JP2024159173A Pending JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンa

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159173A Pending JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンa

Country Status (7)

Country Link
US (3) US10792276B2 (cg-RX-API-DMAC10.html)
EP (1) EP3787615A1 (cg-RX-API-DMAC10.html)
JP (2) JP7557374B2 (cg-RX-API-DMAC10.html)
CN (1) CN112512517A (cg-RX-API-DMAC10.html)
BR (1) BR112020022159A2 (cg-RX-API-DMAC10.html)
MX (2) MX2020011619A (cg-RX-API-DMAC10.html)
WO (1) WO2019211294A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.
US20220241240A1 (en) * 2019-01-18 2022-08-04 Societe Des Produits Nestle S.A. Agents and methods for increasing stem cell function
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
JP7897572B2 (ja) * 2020-11-26 2026-07-30 株式会社ダイセル サーチュイン6活性化剤
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof
AU2022270331A1 (en) * 2021-05-05 2023-10-12 Ludwig Institute For Cancer Research Urolithin for increasing stem cell function
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN117180267B (zh) * 2023-10-25 2026-03-13 深圳市第三人民医院(深圳市肝病研究所) 一种尿石素a在制备药物中的应用及药物
WO2025224366A1 (en) * 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers
GB202417829D0 (en) * 2024-12-04 2025-01-15 Amazentis Sa Formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646177T3 (es) 2006-04-26 2017-12-12 The Regents Of The University Of California Usos terapéuticos de las urolitinas
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
US20170367390A1 (en) * 2014-12-19 2017-12-28 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
US20170304263A1 (en) * 2016-04-20 2017-10-26 John Michael Pezzuto Antioxidative stress compositions, methods of preparing and uses thereof
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.

Similar Documents

Publication Publication Date Title
Rappuoli et al. Transforming vaccinology
Garçon et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach
Altenburg et al. Virus-specific T cells as correlate of (cross-) protective immunity against influenza
JP2017523180A5 (cg-RX-API-DMAC10.html)
JP2021534183A5 (cg-RX-API-DMAC10.html)
TW200722101A (en) Novel composition
Hsu A brief history of vaccines: smallpox to the present.
JP2011504486A5 (cg-RX-API-DMAC10.html)
MX2007008010A (es) Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
JP2021505648A5 (cg-RX-API-DMAC10.html)
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
Garg et al. Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain
JP2016502996A (ja) ナイーブな対象のためのワクチン組成物
JP2011525902A (ja) 遅延型追加刺激免疫処置に対する迅速な応答
WO2017122635A1 (ja) 固定化ウイルス粒子を含むワクチン
Depelsenaire et al. Introduction to vaccines and vaccination
JP2023099200A (ja) アジュバントおよび該アジュバントを含むワクチン
JP2017509713A5 (cg-RX-API-DMAC10.html)
RU2016141621A (ru) Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин
Rehmani et al. The influence of adjuvants on oral vaccination of chickens against Newcastle disease
Modjarrad et al. Human vaccines: emerging technologies in design and development
CN101820904A (zh) 引起针对大流行性流感病毒的免疫应答的方法
Rockman et al. Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines
Adlard et al. Influenza immunization in children with cystic fibrosis
Hay What you need to know